CA3000209C - Anticorps anti-lag3 et leurs utilisations - Google Patents

Anticorps anti-lag3 et leurs utilisations

Info

Publication number
CA3000209C
CA3000209C CA3000209A CA3000209A CA3000209C CA 3000209 C CA3000209 C CA 3000209C CA 3000209 A CA3000209 A CA 3000209A CA 3000209 A CA3000209 A CA 3000209A CA 3000209 C CA3000209 C CA 3000209C
Authority
CA
Canada
Prior art keywords
antibody
lag3
amino acid
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3000209A
Other languages
English (en)
Other versions
CA3000209A1 (fr
Inventor
Erica ULLMAN
Aynur HERMANN
Ella Ioffe
Elena Burova
Gavin Thurston
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority claimed from PCT/US2016/056156 external-priority patent/WO2017062888A1/fr
Publication of CA3000209A1 publication Critical patent/CA3000209A1/fr
Application granted granted Critical
Publication of CA3000209C publication Critical patent/CA3000209C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des anticorps qui se lient à la protéine du gène d'activation des lymphocytes 3 (LAG3) co-inhibitrice des cellules T, et des procédés d'utilisation. Dans divers modes de réalisation de l'invention, les anticorps sont des anticorps entièrement humains qui se lient à LAG3. Dans certains modes de réalisation, les anticorps de l'invention sont utiles pour inhiber ou neutraliser l'activité de LAG3, en donnant ainsi un moyen de traitement d'une maladie ou d'un trouble tel qu'un cancer ou une infection virale.
CA3000209A 2015-10-09 2016-10-07 Anticorps anti-lag3 et leurs utilisations Active CA3000209C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562239524P 2015-10-09 2015-10-09
US62/239,524 2015-10-09
US201562257791P 2015-11-20 2015-11-20
US62/257,791 2015-11-20
US201662315119P 2016-03-30 2016-03-30
US62/315,119 2016-03-30
US201662359921P 2016-07-08 2016-07-08
US62/359,921 2016-07-08
US201662365006P 2016-07-21 2016-07-21
US62/365,006 2016-07-21
PCT/US2016/056156 WO2017062888A1 (fr) 2015-10-09 2016-10-07 Anticorps anti-lag3 et leurs utilisations

Publications (2)

Publication Number Publication Date
CA3000209A1 CA3000209A1 (fr) 2017-04-13
CA3000209C true CA3000209C (fr) 2025-08-12

Family

ID=

Similar Documents

Publication Publication Date Title
US20240166740A1 (en) Anti-lag3 antibodies and uses thereof
JP7562606B2 (ja) Ｐｄ－１に対するヒト抗体
AU2018307675A1 (en) Anti-CTLA-4 antibodies and uses thereof
CA3000209C (fr) Anticorps anti-lag3 et leurs utilisations
CA3070790C (fr) Anticorps anti-ctla-4 et leurs utilisations
HK40070794A (en) Human antibodies to pd-1
EA039718B1 (ru) Антитела к lag3 и их применения
BR122025018289A2 (pt) Anticorpo isolado ou fragmento de ligação a antígeno, seu uso, composição farmacêutica, molécula de polinucleotídeo isolado, vetor e célula
BR112018007046B1 (pt) Anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga especificamente à proteína do gene 3 (lag3) de ativação do linfócito humano e seu uso, composição farmacêutica, molécula de polinucleotídeo isolado e vetor
BR112016016699B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a pd-1, método de produção e usos do mesmo, composição farmacêutica, molécula de polinucleotídeo isolada, e vetor
HK1228406B (en) Human antibodies to pd-1